Search hospitals > Tennessee > Nashville
Vanderbilt-Ingram Cancer Center
Claim this profileNashville, Tennessee 37212
Global Leader in Cancer
Global Leader in Parotid Gland Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Lung Cancer
Conducts research for Lymphoma
1090 reported clinical trials
68 medical researchers
Summary
Vanderbilt-Ingram Cancer Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Parotid Gland Cancer, Adult T-Cell Leukemia/Lymphoma, Lung Cancer, Lymphoma and other specialties. Vanderbilt-Ingram Cancer Center is involved with conducting 1,090 clinical trials across 865 conditions. There are 68 research doctors associated with this hospital, such as Scott Borinstein, M.D., Michael Gibson, Elizabeth J. Davis, and Debra L. Friedman.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Scott Borinstein, M.D.Vanderbilt University/Ingram Cancer Center8 years of reported clinical research
Expert in Cancer
Expert in Rhabdomyosarcoma
32 reported clinical trials
53 drugs studied
Michael GibsonVanderbilt University/Ingram Cancer Center4 years of reported clinical research
Studies Parotid Gland Cancer
Studies Squamous Cell Carcinoma
18 reported clinical trials
37 drugs studied
Elizabeth J. DavisVanderbilt University/Ingram Cancer Center5 years of reported clinical research
Studies Cancer
Studies Soft Tissue Sarcoma
18 reported clinical trials
24 drugs studied
Debra L. FriedmanVanderbilt University/Ingram Cancer Center5 years of reported clinical research
Studies Cancer
Studies Adult T-Cell Leukemia/Lymphoma
16 reported clinical trials
49 drugs studied
Clinical Trials running at Vanderbilt-Ingram Cancer Center
Cancer
Lung Cancer
Breast Cancer
Multiple Myeloma
Colorectal Cancer
Solid Tumors
Parotid Gland Cancer
Skin Cancer
Acute Lymphoblastic Leukemia
Testicular cancer
Immunotherapy + Radiation
for Head and Neck Cancer
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Recruiting2 awards Phase 2
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting2 awards Phase 310 criteria
Pump Chemotherapy
for Colorectal Cancer
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metastatic colorectal cancer to the liver, but it is only available at a small number of hospitals, and most of the time it is not used until standard chemotherapy stops working. Standard chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding HAI to standard chemotherapy may be effective in shrinking or stabilizing unresectable colorectal liver metastases.
Recruiting2 awards Phase 37 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Vanderbilt-Ingram Cancer Center?
Where is Vanderbilt-Ingram Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Vanderbilt-Ingram Cancer Center accept?
What awards or recognition has Vanderbilt-Ingram Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.